Takamichi Uchiyama

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial

Hiroyuki Suzuki, Masaru Terai, Shigeto Fuse et al. · The Lancet · 2019 · 208 citations

Medicine, Cardiology, Immunology +11

Role of Akt Signaling in Mitochondrial Survival Pathway Triggered by Hypoxic Preconditioning

Takamichi Uchiyama, Richard M. Engelman, Nilanjana Maulik et al. · Circulation · 2004 · 183 citations · Full text

Life Sciences, Cardiology, Cell Biology +16

Nitric Oxide Induces Caspase-dependent Apoptosis and Necrosis in Neonatal Rat Cardiomyocytes

Takamichi Uchiyama, Hajime Otani, Takayuki Okada et al. · Journal of Molecular and Cellular Cardiology · 2002 · 78 citations

Life Sciences, Cell Biology, Physiology +11

Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning

Reiji Hattori, Hajime Otani, Takamichi Uchiyama et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2001 · 57 citations

Medicine, Biochemistry, Cardiology +13

N-Terminal Pro-Brain Natriuretic Peptide and Risk of Coronary Artery Lesions and Resistance to Intravenous Immunoglobulin in Kawasaki Disease

Ken Yoshimura, Takahisa Kimata, Kenji Mine et al. · The Journal of Pediatrics · 2013 · 39 citations

Medicine, Cardiology, Internal Medicine +5